Recent article by Shields et al titled "adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion".
Bennett
Matthew
M
Reynolds
Ashley S
AS
Dickerman
Rob D
RD
D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D002574:Cervical Vertebrae / Q000601:surgery*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008159:Lumbar Vertebrae / Q000601:surgery; D008875:Middle Aged; D009221:Myositis Ossificans / Q000139:chemically induced; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013123:Spinal Fusion; D016212:Transforming Growth Factor beta / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use
C525718:BMP2 protein, human; C525819:BMP7 protein, human; D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta